A prospective randomized control trial comparing the effect of Chloramphenicol ointment with Recombinant Human Epidermal Growth Factor on facial burn wound healing

Not Applicable

• Conditions: Second degree burn wound Facial burn wound healingRecombinant Human Epidermal Growth Factor promote wound healing; Burn; Facial burn; Burn wound healing; Chloramphenicol ointment; Recombinant Human Epidermal Growth Factor; rhEGF

• Registration Number: TCTR20171004003
• Lead Sponsor: Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-10-04
• Study Completion: 2019-04-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

- Age 18-65 years old
- Second degree facial burn wound area > 1 %BSA
- Burn in 48 hours

Exclusion Criteria

- Immunocompromised host
- Using steroids, chemotherapy, immunosuppressive drugs
- Allergy to chloramphenicol, recombinant human epidermal growth factor or Isopropyl p-Hydroxybenzoate
- Breast feeding or pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Complete healing day Evaluate every 2 days Area of granulation tissue that measure from eKare inSightâ„¢ 3D Wound

Secondary Outcome Measures

Name	Time	Method
Effect of drug on wound pain Evaluate every 2 days after change wound dressing for 30 minutes Numeric pain score [0 to 10],Effect of drug on wound infection rate Evaluate every 2 days Fever, Wound appearance; erythema, swelling, pus discharge, fever, swab culture ; bacteria >10^5 CFU,Effect of drug on scar appearance 2,6 months after complete healing wound Vancouver scar scale,Side effects of drug Evaluate every 2 days after change wound dressing for 30 minutes Rash Irritation